However, NF-κB deficiency can lead to severe immunodeficiency and long-term inhibition of NF-κB causes serious side effects, suggesting that an appropriate dosage regimen and administration time will facilitate NF-κB targeted therapy in the clinic.764 Moreover, multiple other inhibitors such as antibodies, cytokines and chemokines inhibitors, and inhibitors of inflammatory transcription factors, are in clinical trials and the results are eagerly anticipated. The gene discussed is NFKB1; the disease is Immunodeficiency.